natgillin/translations-raw huggingface dataset:
150 doses
1 x 150 odmerki
150 doses
150 odmerkov
150 film-coated tablets
150 filmsko obloženih tablet
150 IU (300 IU/mL) recombinant follicle-stimulating hormone (FSH) activity.
150 i.e. (300 i.e./ml) aktivnosti rekombinantnega folikle stimulirajočega hormona (FSH).
150 IU r-hFSH
150 i.e. r-hFSH
150 IU r-hFSH
Vsebina
150 IU r-hFSH/75 IU r-hLH
150 i.e.r-hFSH/75 i.e.r-hLH
150 IU/0.18 mL
200 i.e./0,5 ml
150 IU/0.25 ml
150 i.e./0,25 ml
150 IU/0.5 mL
150 i.e./0,5 ml
150 IU/kg 3x/week
150 i.e./kg 3-krat na teden
150 IU/kg 3x/week or 450 IU/kg once weekly
150 i.e./kg, 3-krat na teden ali 450 i.e./kg, enkrat na teden
150 mg (1.5 ml) twice daily
150 mg (1,5 ml) dvakrat na dan
150 mg 3 times per week on set
150 mg 3-krat na teden na določene
150 mg and 500 mg film-coated tablets
150 mg in 500 mg filmsko obložene tablete
150 mg bid with monitoring.
150 mg dvakrat na dan in bolnika spremljati.
150 mg every other day
150 mg vsak drug dan
150 mg film-coated tablets Ibandronic acid
150 mg filmsko obložene tablete ibandronska kislina
150 mg for patients with body weight > 40 kg
150 mg za bolnike s telesno maso > 40 kg
150 mg for patients with body weight more than 40 kg
150 mg za bolnike s telesno maso več kot 40 kg
150 mg lamivudine
150 mg lamivudina
150 mg of powder for solution for injection in a vial (type I glass) with a stopper (coated chlorobutyl rubber) and flip-off cap (aluminium).
150 mg praška za raztopino za injiciranje v viali (iz stekla tipa I) z zamaškom (iz obložene klorobutilne gume) in z dvižno zaporko (iz aluminija).
150 mg once daily.
elvitegravirja 150 mg enkrat na dan.
150 mg once every other day
150 mg enkrat vsak drugi dan
150 mg once monthly (N=320)
150 mg enkrat na mesec
150 mg pen Figure A
Slika A
150 mg praziquantel & 30 mg emodepside
prazikvantela & 30 mg
150 mg simeprevir 12 weeks
150 mg simeprevir 12 tednov
150 mg suspension for injection
150 mg suspenzija za injiciranje
150 mg tablet: yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172) 200 mg tablet: indigo carmine aluminium lake (E132)
150 mg tableta: rumeni železov oksid (E172), rdeči železov oksid (E172), črni železov oksid (E172) 200 mg tableta: indigotin (E132)
150 mg twice daily when
150 mg dvakrat na dan
150 mg twice daily, geometric mean Cmax, AUC(0-) and predose concentration (C) were 1478 ng/ml, 4341 ng*hr/ml and 26 ng/ml, respectively.
Po uporabi 150 mg dvakrat na dan so bila geometrična povprečja Cmax 1478 ng/mL, AUC(0-) 4341 ng*h/mL in koncentracije pred odmerkom (C) 26 ng/mL.
150 mg twice weekly on set days is
v odmerku 150 mg 3-krat na teden
150 mg/2 weeks or 300 mg/4 weeks
150 mg/2 tedna ali 300 mg/4 tedne
150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg) tablets, Corbilta dosing should be carefully titrated for optimal clinical response.
200 mg/50 mg/200 mg), je treba za dosego optimalnega kliničnega odgovora odmerjanje zdravila Corbilta skrbno titrirati.
150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg) tablets, Stalevo dosing should be carefully titrated for optimal clinical response.
150 mg/37,5 mg/200 mg ali 175 mg/43,75 mg/200 mg ali 200 mg/50 mg/200 mg), je treba za dosego optimalnega kliničnega odgovora odmerjanje zdravila Stalevo skrbno titrirati.
150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg) tablets, Corbilta dosing should be carefully titrated for optimal clinical response.
125 mg/31,25 mg/200 mg ali 175 mg/43,75 mg/200 mg ali 150 mg/37,5 mg/200 mg), je treba za dosego optimalnega kliničnega odgovora odmerjanje zdravila Corbilta skrbno titrirati.
150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg) tablets, Stalevo dosing should be carefully titrated for optimal clinical response.
125 mg/31,25 mg/200 mg ali 175 mg/43,75 mg/200 mg ali 150 mg/37,5 mg/200 mg), je treba za dosego optimalnega kliničnega odgovora odmerjanje zdravila Stalevo skrbno titrirati.
150 mg/4 weeks) to placebo, all three doses of Xeplion were superior to placebo in improving the PANSS total score.
Vsi trije odmerki zdravila Xeplion so bili učinkovitejši od placeba pri izboljševanju skupne vrednosti lestvice PANSS.
150 mg/m² once daily, to be increased in the second cycle to 200 mg/m² once daily, for 5 days if there is no haematological toxicity (see section 4.4)
V drugem ciklu se poveča na 200 mg/m² enkrat dnevno, in sicer za pet dni, če ni hematološke toksičnosti (glejte poglavje 4.4).
150 micrograms PRE-FILLED SYRINGES LABEL
NALEPKA ZA NAPOLNJENO INJEKCIJSKO BRIZGO 150 mikrogramov
150 micrograms), separated at least by 2 infusion-free calendar days (for example you will receive infusion on day 0, 3, 7, 10).
150 mikrogramov), med katerimi morata biti vsaj 2 koledarska dneva brez infundiranja (infuzijo boste na primer prejeli na dan 0, 3, 7, 10).
150 ml oral solution
150 ml peroralne raztopine.
150 ml oral solution 150 ml oral solution 300 ml oral solution
150 ml peroralna raztopina 150 ml peroralna raztopina 300 ml peroralna raztopina
150 or 300 mg QD
150 ali 300 mg na dan
150 patients originally randomised to placebo + MTX in Trial 1 received at least one course of RTX + MTX by one year
150 bolnikov, ki so v preskušanju 1 sprva prejemali placebo + metotreksat, je do enega leta prejelo vsaj en cikel rituksimaba
150 tablets
150 filmsko obložene tablete
150 tablets
150 tablet
150 tablets
150 tablete
150 to <300 cells/L
150 do < 300 celic/l
150-772 or equivalent, dimensions: approximately 0.5-1 cm x 6 cm)
150-772 ali ekvivalentne, dimenzije: približno 0,5–1 cm x 6 cm);
150/100 mg once daily.
150/100 mg enkrat dnevno.
150/600/100 mg twice
300 mg b.i.d.).
1500 IU octocog alfa
1500 i.e. oktokoga alfa
1500-2000 mg/day (n=268)
Sitagliptin 100 mg enkrat na dan (n=315)
153 (35.3)a
153 (35,3) a
153 51 Pallini Attiki, Greece
153 51 Pallini Attiki, Grčija
153 51 Pallini Attiki, Greece
15351 Pallini Attiki Grčija
15351 Pallini Attiki Greece
15351 Pallini Attiki Grčija
15351 Pallini Attiki Greece‌‌
15351 Pallini Attiki Grčija
15351 Pallini Attiki, Greece
153 51 Pallini Attiki, Grčija
15351 Pallini GREECE
15351 Pallini GRČIJA
15351 Pallini, Attiki Greece
153 51 Pallini, Attiki Grčija
15351 Pallini, Attiki Greece
15351 Pallini, Attiki Grčija
15351 Pallini, Attiki Greece
Izdelovalca:
156 cells/mm3 (4.6 %)
156 celic/mm3 (4,6 %)
1560 IU/5 ml
1560 i.e./5 mL
159 keV photopeak and a ± 10% energy window.
Energijska odstopanja so lahko ± 10 %.
15Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high (≥ 5.17 mmol/l) were observed commonly.
15 Pogosto so opazovali spremembe v ravneh celokupnega holesterola na tešče z normalnih osnovnih vrednosti (< 4,39 mmol/l), ki so se povišale na visoke (≥ 5,17 mmol/l).
15mg of desirudin
15 mg desirudina
15mg of powder in a vial and 0.5ml of solvent in an ampoule Pack size of 1
15 mg praška v viali in 0,5 ml vehikla v ampuli Pakiranje z 1 vialo
15mg of powder in a vial and 0.5ml of solvent in an ampoule Pack size of 10
15 mg praška v viali in 0,5 ml vehikla v ampuli Pakiranje z 10 vialami
15mg of powder in a vial and 0.5ml of solvent in an ampoule Pack size of 2
15 mg praška v viali in 0,5 ml vehikla v ampuli Pakiranje z 2 vialama
16
tedni
16 (13)
56 (18)b
16 (24.6%), p<0.0001
16 (24,6 %), p<0,0001
16 Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.
16O povečanih plazemskih koncentracijah prolaktina so poročali pri 47,4 % mladostnikov.
16 hours
16 ur
16 IU
16 i.e.
16 January 2009
16. januar 2009
16 July 2009
{datum}
16 mg/kg Once- Daily Dosing Geometric Mean (95% Cl)
16 mg/kg enkrat na dan, geometrična sredina (95 % IZ)
16 tablets
16 tablet
16 to 26-year-old women
Ženske, stare od 16 do 26 let
16 to 26-years of age men
Moški, stari od 16 do 26 let
16 to 26-years of age women
Ženske, stare od 16 do 26 let
16 weeks (n = 35)
16 tednov (n = 35)
16 weeks (n = 63)
16 tednov (n = 63)
16 weeks (n = 98)a
16 tednov (n = 98)a
16 weeks after vaccination (Mycoplasma hyopneumoniae)
16 tednov po cepljenju Mycoplasma hyopneumoniae.
16 Weeks N=58
16 tednov n = 58
16 Weeks N=8
16 tednov n = 8
16 weeks of treatment may be associated with a lower chance of response and is associated with a higher risk of relapse than a 24 week treatment duration (see section 5.1).
16- tedensko zdravljenje je lahko povezano z manjšo možnostjo odziva in tveganje za ponovitev bolezni je večje kot pri 24-tedenskem zdravljenju (glejte poglavje 5.1).
16%
23 %g
16% (n = 50)
16 % (n = 50)
16% for deferoxamine).
16 % pri deferoksaminu).
16% of patients had <6 bone metastases, 44% of patients had between 6 and 20 bone metastases, 40% of patients had more than 20 bone metastases or superscan.
16 % bolnikov je imelo < 6 metastaz v kosteh, 44 % bolnikov je imelo med 6 in 20 metastaz v kosteh, 40 % bolnikov je imelo več kot 20 metastaz v kosteh ali intenzivno difuzno kopičenje po celotnem skeletu (t. i. superscan).
16- Through 26-Year-Old Boys and Men
Dečki in moški, stari od 16 do 26 let
16- Through 26-Year-Old Girls and Women†
Deklice in ženske, stare od 16 do 26 let
16.5 mg once daily
16,5 mg enkrat na dan
16.5 mg twice daily
16,5 mg dvakrat na dan
16.7% (Mayo regimen); p <0.0002. The median time to progression was 140 days (capecitabine) vs.
Mediana časa do napredovanja bolezni je bila 140 dni (kapecitabin) v primerjavi s 144 dnevi (shema Mayo).
16.8 micrograms
16,8 mikrogramov
16.INFORMATION IN BRAILLE
PODATKI V BRAILLOVI PISAVI
16/04/2009
DD/mesec LLLL
16/84 vs.
v pr. z 39/81
160 (37.0)a
160 (37,0) a
160 g sachet – 2 years.
160 g vrečka - 2 leti
160 g sachet: do not store above 25 ºC. 400 g sachet: do not store above 25 °C.
160 g vrečka: Ne shranjujte pri temperaturi nad 25 C 400 g vrečka: Ne shranjujte pri temperaturi nad 25 C
160 mg single-use vial containing powder for concentrate for infusion solution delivers 8 mL of 20 mg/mL of trastuzumab emtansine after reconstitution
Po rekonstituciji 160-mg viale za enkratno uporabo s praškom za koncentrat za raztopino za infundiranje dobimo 8 ml trastuzumaba emtanzina 20 mg/ml.
160 mg single-use vial containing powder for concentrate for infusion solution delivers 8 mL of 20 mg/mL of trastuzumab emtansine after reconstitution (see section 6.6).
Po rekonstituciji 160-mg viale za enkratno uporabo s praškom za koncentrat za raztopino za infundiranje dobimo 8 ml trastuzumaba emtanzina s koncentracijo 20 mg/ml (glejte poglavje 6.6).
160 mg trastuzumab emtansine vial: Using a sterile syringe, slowly inject 8 mL of sterile water for injection into the vial.
160-mg viala trastuzumaba emtanzina: S sterilno injekcijsko brizgo počasi injicirajte v vialo 8 ml sterilne vode za injekcije.
160/4.5 µg bd + formoterol 4.5 µg as needed
2-krat na dan + formoterol 4,5 µg po potrebi
160/80 m g N=76
160/80 mg n = 76
160/80 m g N=76
N=111 23 (20.7%)
160/80 mg N=76
160/80 mg n = 76
1600
1600 kalorij
1600 (2 x 20 cartridges x 40) tablets (multipack)
1600 (2 x 20 vložki x 40) tablet (skupno pakiranje)
1600/100 mg qd)
(sakvinavir/ritonavir
162
placebo
167 IU/mL after reconstitution)
167 i.e./ml po rekonstituciji)
167.8
(dyn·s·cm-5)
168 (2 x 84) tablets
168 (2 x 84) tablet
168 (3 x 56) tablets
168 (3 x 56) tablet
168 (3 x 56) tablets (multipack)
168 (3 x 56) tablet (skupno pakiranje)
168 (3 x 56) tablets (multipack)
168 (3 x 56) tablet (večkratno pakiranje)
168 (3 x 56) tablets (multipack)
Velikost  ja) pakiranja
168 (3x56) tablets
168 (3x56) tablet
168 (4 x 42) ampoules (multipack)
168 (4 x 42) ampul (večkratno pakiranje)
168 (4 x 42) ampoules + co- packed with device consumable set (multipack)
168 (4 x 42) ampul + priloženi set za uporabo medicinskega
168 (4 x 42) ampoules + co- packed with device consumable set (multipack)
168 (4 x 42) ampul + priloženi set za uporabo medicinskega pripomočka (večkratno pakiranje)
168 (4 x 42) AMPOULES WITH 1 ML CO-PACKED WITH BREELIB CONSUMABLES SET
168 (4 X 42) AMPUL Z 1 ML S PRILOŽENIM SETOM ZA UPORABO NEBULATORJA BREELIB
168 (4x42) ampoules co-packed with Breelib consumables set (containing 1 mouthpiece and 1 medication chamber).
168 (4 x 42) ampul, ki jim je priložen set za uporabo nebulatorja Breelib (1 ustnik in 1 prostor za zdravilo).
168 capsules
168 kapsul
168 Christopher Street MT-VLT02 Valletta Tel: + 356-21 23 21 75
MT-VLT02 Valletta Tel: + 356-21 23 21 75
168 film-coated tablets (4 bottles containing 42 tablets each) The bottles are not to be distributed individually.
168 filmsko obloženih tablet (4 plastenke, ena plastenka vsebuje 42 filmsko obloženih tablet) Plastenk se ne sme izdajati posamezno.
168 hard capsules
168 trdih kapsul
168 tablets
168 tablet
168 tablets
tablet (multi
168 tablets
tablet (multi pakiranje)
168 tablets
uporaba
168 tablets (3x56)
168 tablet (3x56)
168, 196 modified-release tablets, multi-packs containing 196 (2 packs of 98) modified-release tablets and 49 x 1 modified-release tablets in perforated unit dose blister.
196 (2 pakiranji po 98) tabletami s prirejenim sproščanjem in z 49 x 1 tableto s prirejenim sproščanjem v perforiranem pretisnem omotu za enkratni odmerek.
168.0 micrograms
168,0 mikrogramov
16Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.
16 O zvišanih plazemskih koncentracijah prolaktina so poročali pri 47,4 % mladostnikov.
17 (26.2%), p<0.0001
17 (26,2 %), p<0,0001
17 hours
17 ur
17 kg to < 22 kg and 22 kg to < 28 kg, respectively.
17 kg do < 22 kg oziroma 22 kg do < 28 kg.
17 kg to < 22 kg and 28 kg to < 35 kg, respectively.
17 kg do < 22 kg oziroma 28 kg do < 35 kg.
17 kg to < 22 kg who are able to swallow film-coated tablets is one 123 mg tablet once daily taken orally with food.
17 kg do < 22 kg, ki lahko pogoltnejo filmsko obložene tablete, je ena 123 mg tableta enkrat dnevno, peroralno, s hrano.
17 ml solution for infusion contains 510 mg of iron as ferumoxytol.
17 ml raztopine za infundiranje vsebuje 510 mg železa v obliki ferumoksitola.
17 October 2003/17 October 2008
17. oktober 2003/17. oktober 2008
17 were included in the MITT efficacy analyses.
17 bolnikov vključili v analize učinkovitosti MITT.
17 -Ethinyl estradiol 35 μg qd x
17 -etinilestradiol 35 μg enkrat
17.2 mos (13.9, 19.2)
17,2 meseca (13,9, 19,2)
17.3 (11.8, NA)
17,3 (11,8, np)
17.33 (12.54 – 22.91) h
17,33 (12,54-22,91) h
17.4 mg pyriproxifen, 1,429 mg permethrin
17.4 mg piriproksifen, 1429 mg permetrin
17.5 and 35.1 mL: Once opened use within 28 days.
17,5 ml in 35,1 ml plastenka: 28 dni
17.5 mg/m2/day on four consecutive days (Days 4–7) of Courses 1–5.
4. do 7. dne) v ciklih od 1 do 5.
17.7 hours and 73.3 hours, respectively.
17,7 ure, sirolimusa pa 73,3 ure.
17.8)
OS (tedni)e
17.UNIQUE IDENTIFIER – 2D BARCODE
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
170
DOE
170 00 Praha 7 Czech Republic
170 00 Praha 7 Češka
170 00, Praha 7 Czech republic
170 00, Praha 7 Češka
170 ml oral solution.
170 ml, peroralna raztopina.
170.4 micrograms/mL (Cmax) at 0.5 hour postdose (end of infusion), 7.0 micrograms/mL at 12 hour postdose, and 1.1 microgram/mL at 24 hour postdose.
170,4 mikrogramov/ml (Cmax) 0,5 ure po odmerku (ob koncu infuzije), 7,0 mikrogramov/ml 12 ur po odmerku in 1,1 mikrograma/ml 24 ur po odmerku.
17000 Praha 7 Czech Republic
170 00 Praga 7 Češka
17000 Praha 7 Czech Republic czech.info@valeant.com
170 00 Praga 7 Češka czech.info@valeant.com
171 115 97 85 75 70 64 34 5 0
171 115 97 85 75 70 64 34 5 0 ipilimumab
17170 Amer SPAIN
Farners pk 21,6 17170 Amer SPAIN
172 rue de Charonne 75011 Paris
172 rue de Charonne 75011 Pariz
172 rue de Charonne 75011 Paris - France
172 rue de Charonne 75011 Pariz – Francija
172mL p<0.001 (87, 258)
172 ml p < 0,001 (87, 258)
173 D-55216 Ingelheim am Rhein, Germany.
173 D-55216 Ingelheim am Rhein, Nemčija
173 D-55216 Ingelheim am Rhein, Germany.
173 D-55216 Ingelheim am Rhein, Nemčija.
174 56 Alimos, Athens, Greece.
174 56 Alimos, Atene, Grčija
174 and 251 head and neck cancer patients who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
174 in 251 bolnikih z rakom glave in vratu, ki so dobivali docetaksel v kombinaciji s cisplatinom in 5-fluorouracilom (navedeni so klinično pomembni, z zdravljenjem povezani, neţeleni učinki).
174 and 251 head and neck cancer patients who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
174 in 251 bolnikih z rakom glave in vratu, ki so dobivali docetaksel v kombinaciji s cisplatinom in 5-fluorouracilom (navedeni so klinično pomembni, z zdravljenjem povezani, neželeni učinki).
174 and 251 head and neck cancer patients who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
174 in 251 bolnikih z rakom glave in vratu, ki so prejemali docetaksel v kombinaciji s cisplatinom in 5-fluorouracilom ( navedeni so klinično pomembni, z zdravljenjem povezani, neželeni učinki).
174 and 251 head and neck cancer patients who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
174 in 251 bolnikih z rakom glave in vratu, ki so prejemali docetaksel v kombinaciji s cisplatinom in 5-fluorouracilom (navedeni so klinično pomembni, z zdravljenjem povezani, neželeni učinki).
174 and 251 head and neck cancer patients who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
174 in 251 bolnikih z rakom glave in vratu, ki so prejemali docetaksel v kombinaciji s cisplatinom in 5-fluorouracilom (predstavljeni so klinično pomembni, z zdravljenjem povezani, neželeni učinki).
174 and 251 head and neck cancer patients who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
174 in 251 bolnikov z rakom glave in vratu, ki so prejemali docetaksel v kombinaciji s cisplatinom in 5-fluorouracilom (navedeni so klinično pomembni, z zdravljenjem povezani, neželeni učinki).
17493 Greifswald Insel Riems Germany
17493 Greifswald Insel Riems Nemčija
175 mg (2.2 ml) twice daily
175 mg (2,2 ml) dvakrat na dan
175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg) tablets, Corbilta dosing should be carefully titrated for optimal clinical response.
150 mg/37,5 mg/200 mg ali 175 mg/43,75 mg/200 mg ali 200 mg/50 mg/200 mg), je treba za dosego optimalnega kliničnega odgovora odmerjanje zdravila Corbilta skrbno titrirati.
175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg) tablets, Stalevo dosing should be carefully titrated for optimal clinical response.
150 mg/37,5 mg/200 mg ali 175 mg/43,75 mg/200 mg ali 200 mg/50 mg/200 mg), je treba za dosego optimalnega kliničnega odgovora odmerjanje zdravila Stalevo skrbno titrirati.
175 mg/43.75 mg/200 mg) tablets, Levodopa/Carbidopa/Entacapone Orion dosing should be carefully titrated for optimal clinical response.
150 mg/37,5 mg/200 mg ali 175 mg/43,75 mg/200 mg), je treba za dosego optimalnega kliničnega odgovora odmerjanje zdravila Levodopa/Carbidopa/Entacapone Orion skrbno titrirati.
175 tablets
175 tablet
1750 IU
1750 IE
1750 IU of antithrombin alfa
1750 i.e. antitrombina alfa
177Lu-Lutetium has a half-life of 6.647 days.
Lutecij 177Lu ima razpolovni čas 6,647 dneva.
17813 Vall de Bianya SPAIN
17813 Vall de Bianya ŠPANIJA
1795.6
mME§/ml
17p deletion
Delecija 17p
17p or 11q deletion (n=90)
Delecija 17p ali 11q (n = 90)
18 (7.3%)
Psoriaza s plaki
18 ampoules
18 ampul
18 ampoules (3x6)
18 ampu (3x6)
18 blisters of
18 pretisnih omotov z
18 capsules
18 kapsul
18 mg once daily
18 mg enkrat na dan
18 mg orally once daily
18 mg peroralno enkrat na dan
18 mg torasemide
18 mg toresamida
18 mg/h) of the above prepared solution over the 3 hour period under adequate medical supervision in an obstetric unit.
18 mg/uro) v 3 urah pod ustreznim zdravniškim nadzorom na porodnem oddelku.
18 micrograms once daily) study, both in patients with clinical diagnosis of moderate to severe COPD.
V obe navedeni študiji so bili vključeni bolniki s klinično diagnozo zmerne do hude KOPB.
18 million
18 milijonov
18 million
25 milijonov
18 million
30 milijonov
18 million
milijonov i.e./ml)
18 million IU
18 milijonov i.e.
18 million IU in doses ranging from 1.5 to 6 million IU.
18 milijonov i.e., lahko odmerjamo v razponu od 1,5 do 6 milijonov i.e.
18 million IU solution for injection in multidose pen 1 pen, 12 injection needles and 12 cleansing swabs 2 pens, 24 injection needles and 24 cleansing swabs 8 pens, 96 injection needles and 96 cleansing swabs
18 milijonov i.e. raztopina za injiciranje v večodmernem peresniku 1 peresnik, 12 injekcijskih igel in 12 čistilnih tamponov 2 peresnika, 24 injekcijskih igel in 24 čistilnih tamponov 8 peresnikov, 96 injekcijskih igel in 96 čistilnih tamponov
18 million IU solution for injection multidose pen 1 pen, 12 injection needles and 12 cleansing swabs
18 milijonov i.e. raztopina za injiciranje v večodmernem peresniku 1 peresnik, 12 injekcijskih igel in 12 čistilnih tamponov
18 million IU/3 ml
18 milijonov i.e./3 ml
18 million IU/3 ml solution for injection 1 multiple dose vial
18 milijonov i.e./3 ml raztopina za injiciranje 1 viala z večkratnimi odmerki
18 million IU/3mL
18 milijonov
18 million IU/pen
18 milijonov i.e./peresnik
18 months Diluted solution
18 mesecev Razredčena raztopina
18 months.
mesecev.
18 orodispersible tablets
18 orodisperzibilnih tablet
18 tablets
18 tablet
18 to 22 kg
18 do 22 kg
18 to 22 kg
18 do < 22 kg
18 to 22 kg*
18 do 22 kg
18 to 59 years
od 18 do 59 let
18 to 59 years N = 99 N = 33
od 18 do 59 let N=99 N=33
18 transdermal patches
18 transdermalnih obližev
18 weeks was approximately 24 mcg/mL at a dose of 2 mg/kg every 3 weeks.
18. tednu je bila ob odmerku 2 mg/kg na 3 tedne približno 24 µg/ml.
18 – 59 years
18–59 let
18 – 59 years 60 years and above
18 – 59 let 60 let in več
18 – 59 years 60 years and above
18–59 let 60 let in več
18% (17) (p=0.016b)
18 % (17) (p = 0,016b)
18% Non-White, 14% Black, 3% Asian, and 1% Multiracial.
3 % Azijcev, 1 % večrasnih.
18-23 months after 2 dose
18–23 mesecev po 2. odmerku
18-23 months after 2 dose
18−23 mesecev po 2. odmerku
18-23 months after 2nd dose
18–23 mesecev po 2. odmerku
18-49 Years N=836-866
18-49 let
18-49 Years Relative to 60-64 Years
18-49 let v primerjavi s 60-64 let
18-60 years
18-60 let
18-Month Survival
18-mesečno preživetje
18-related genital warts was 80.3% (95% CI: 73.9, 85.3) in the combined protocols at end of study.
HPV 18 povezanimi bradavicami na spolovilih pa 80,3 % (95-odstotni IZ: 73,9; 85,3).
18.
18 (17%)b
18.0% p<0.001 (12.0, 23.9)
18,0 % p < 0,001 (12,0, 23,9)
18.1% vs 0%
18,1 % v prim. z 0
18.2 %
Tednom
18.3 mo (16.6, 21.7)
18,3 mesecev
18.5 [15.9, 23.9]
Predhodna izpostavljenost talidomidu
18.7 months median observation time
Mediani čas opazovanja 18,7 meseca
18.9 (2.60)
vrednostmi LS (SE)
18.9 events/1,000 patient-years (p=0.021) a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1,000 patient-years, diet alone 18 events/1,000 patient-years, (p=0.01).
značilno zmanjšanje absolutnega tveganja za miokardni infarkt: metformin-11 primerov/1.000 bolnikov-let, dieta sama–18 primerov/1.000 bolnikov-let (p = 0,01).
18.9 m vs.
18,9 m v prim. s
18.9 months in the placebo arm (HR = 0.60, p = 0.0255).
18,9 meseca v kraku s placebom ((HR = 0,60; p = 0,0255).
18.9 pg/ml for 2-5 yrs and 6-11 yrs, respectively.
11 let, pa 18,9 pg/ml.
18.UNIQUE IDENTIFIER - HUMAN READABLE DATA
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
180 (2 x 90 x 1) tablets
180 (2 x 90 x 1) tablet
180 (2 x 90 x 1) tablets (unit
180 (2 x 90 x 1) tablet
180 (3 x 60 x 1)
(enkratni odmerek) 180 (3 x 60 x 1)
180 (3 x 60) capsules
180 (3 x 60) kapsul
180 (3 x 60) tablets
180 (3x60) tablet
180 (3x60) tablets (multipack)
180 (3x60) tablet (skupno pakiranje)
180 (3x60) tablets (multipack)
180 (3x60) tablet(skupno pakiranje)
180 (6 bottles of 30) film-coated tablets
180 (6 stekleničk po 30) filmsko obloženih tablet
180 capsules
180 kapsul
180 hard capsules
180 trdih kapsul
180 mcg
(n = 177)
180 mcg
(n = 272)
180 mcg
ali 180 g
180 mcg x BSA/1.73 m² + Ribavirin 15 mg/kg (N=55)*
180 µg x TP/1,73 m² + ribavirin 15 mg/kg (n = 55)
180 mg (1.8 ml) twice daily
180 mg (1,8 ml)dvakrat na dan
180 mg red, ovaloid tablets with “NVR” marked on one side and “TSX” on the other.
180 mg rdeče, ovalne tablete z oznako “NVR” na eni ter “TSX” na drugi strani.